Pharmala Biotech报告超过100万美元的收入、对两个新分子的专利并改进了财务健康。 PharmAla Biotech reports over $1 million in revenue, patents two new molecules, and improves financial health.

Pharmala Biotech Holdings是一家专门从事MDMA研究的公司,它报告说,2024年财政收入增加了95%,超过100万美元。 PharmAla Biotech Holdings, a company specializing in MDMA research, reported a 95% increase in revenue to over $1 million for fiscal 2024. 该公司获得两种新分子(APA-01和ALA-002)专利权,并从不列颠哥伦比亚省转移到安大略省。 The company secured patents for two new molecules, APA-01 and ALA-002, and moved from British Columbia to Ontario. PharmAla 的财务状况也有所改善，调整后的 EBITDA 增长了 605,000 美元，并通过私募发行筹集了 156 万美元。 PharmAla also improved its financial health, showing a $605,000 improvement in adjusted EBITDA and raising $1.56 million through a private placement offering.